Patents Examined by Fred H Reynolds
-
Patent number: 11975044Abstract: FSP27 compositions and methods for treating cancers are described.Type: GrantFiled: July 7, 2022Date of Patent: May 7, 2024Assignee: Ohio UniversityInventors: John J. Kopchick, Vishwajeet Puri, Vishva Sharma, Reetobrata Basu
-
Patent number: 11970555Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.Type: GrantFiled: November 12, 2021Date of Patent: April 30, 2024Assignee: BicycleTx LimitedInventors: Ellen Gowans, Gemma Elizabeth Mudd, Michael Rigby, Punit Seth, Michael Skynner, Steven Stanway, Liudvikas Urbonas, Katerine Van Rietschoten
-
Patent number: 11965016Abstract: The present invention relates to new biomimetic mineralized apatite structures. The present invention also relates to processes for the production of new biomimetic mineralized apatite structures based on natural and synthetic protein scaffolds. In particular, the invention provides synthetic crystal having a hierarchical structure formed on an elastin-like polypeptide membrane or hydrogel. The invention also provides methods of making such crystals, both in vivo and in vitro, as well as kits comprising membranes or hydrogels with cross-linking agents and/or mineralization solutions. The invention also provides the use of such structures in methods of treatment.Type: GrantFiled: January 31, 2022Date of Patent: April 23, 2024Assignee: Mintech-V, LLCInventors: Sherif Ahmed Abdelsalam Elsharkawy, Maisoon Al-Jawad, Alvaro Mata Chavarria, Esther Tejeda-Montes
-
Patent number: 11963997Abstract: The present disclosure provides an anti-tumor polypeptide Bax-BH3, a fluorescent polymeric nanomicelle, a preparation method and use thereof, belonging to the technical field of medicines. The anti-tumor polypeptide Bax-BH3 has an amino acid sequence set forth in SEQ ID No: 1; the fluorescent polymeric nanomicelle includes the anti-tumor polypeptide Bax-BH3 and a polymer carrier; and the polymer carrier is a block copolymer RGD-PHPMA-b-Poly(MMA-alt-(Rhob-MA)). In the present disclosure, the anti-tumor polypeptide Bax-BH3 has desirable biocompatibility and biological activity; and the fluorescent polymeric nanomicelle encapsulates the anti-tumor polypeptide Bax-BH3 by the block copolymer RGD-PHPMA-b-Poly(MMA-alt-(Rhob-MA)), with high encapsulation rate and drug loading, and good release performance.Type: GrantFiled: July 15, 2022Date of Patent: April 23, 2024Assignee: Jilin UniversityInventors: Li Xu, Yi Guo, Sijun Huang, Xi Zhang, Mingming Zhang
-
Patent number: 11951153Abstract: Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.Type: GrantFiled: September 26, 2022Date of Patent: April 9, 2024Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Sidney L. Weiss, Ashim K. Mitra, Eugene J. McNally
-
Patent number: 11945882Abstract: Crystals of the compound represented by formula (1), a method for the production thereof, and a method for producing an antibody-drug conjugate using the crystals.Type: GrantFiled: August 30, 2018Date of Patent: April 2, 2024Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tatsuya Yamaguchi, Takashi Kouko, Shigeru Noguchi, Yohei Yamane, Fumikatsu Kondo, Takahiro Aoki, Tadahiro Takeda, Kohei Sakanishi, Hitoshi Sato, Tsuyoshi Ueda, Shinji Matuura, Kei Kurahashi, Yutaka Kitagawa, Tatsuya Nakamura
-
Patent number: 11945846Abstract: Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.Type: GrantFiled: March 9, 2020Date of Patent: April 2, 2024Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Loren D. Walensky, Rida Mourtada
-
Patent number: 11911447Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.Type: GrantFiled: June 16, 2021Date of Patent: February 27, 2024Assignee: Mederis Diabetes LLCInventor: John J. Nestor
-
Patent number: 11884710Abstract: Peptide compounds and compositions containing the peptide compounds and methods for treating various infections, wounds, and skin conditions such as atopic dermatitis. Examples of wounds that may be treated include surface wounds such as lacerations, abrasions, avulsions, incisions, and amputations, pressure sores, bed sores, wounds due to peripheral vascular disease, post-surgical wounds, diabetic ulcers and wounds, burns, ocular wounds and abrasions, ocular ulcers, and treatment of inflammatory conditions such as dry eye. The peptide compounds and compositions may be used as treatments to enhance acceptance of grafts such as skin grafts and organ grafts.Type: GrantFiled: November 22, 2021Date of Patent: January 30, 2024Assignee: The Board of Regents of the University of OklahomaInventors: Heloise Anne Pereira, Anne Kasus-Jacobi, Gina L. Griffith
-
Patent number: 11840581Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.Type: GrantFiled: December 29, 2020Date of Patent: December 12, 2023Assignee: Protagonist Therapeutics, Inc.Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis, David Liu
-
Patent number: 11826464Abstract: Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.Type: GrantFiled: September 1, 2022Date of Patent: November 28, 2023Assignee: Rani Therapeutics, LLCInventors: Mir Imran, Sara Ansaloni, Radhika Korupolu, Joel M. Harris, Mir Hashim
-
Patent number: 11820800Abstract: Disclosed herein are designed heterodimer proteins, monomeric polypeptides capable of forming heterodimer proteins, protein scaffolds including such polypeptides, and methods for using the heterodimer proteins and subunit polypeptides for designing logic gates.Type: GrantFiled: November 4, 2019Date of Patent: November 21, 2023Assignee: UNIVERSITY OF WASHINGTONInventors: Zibo Chen, Scott Boyken, Sherry Bermeo, Robert A. Langan, David Baker
-
Patent number: 11795202Abstract: The invention is in the field of medicine. More specifically, it is in the field of diagnosing tumor angiogenesis status and in the field of medical treatment of a subject who is suffering, suspected to suffer, or might suffer from a tumor in the future. In particular, the invention relates to a fusion polypeptide comprising a foreign antigen and a self antigen, wherein said foreign antigen consists of a polypeptide comprising an amino acid sequence of at least 12-15 amino acid residues, 12-24% of which residues are hydrophilic, bulky amino acid residues selected from the group consisting of histidine, glutamate, arginine, glutamine, aspartic acid and/or lysine.Type: GrantFiled: August 4, 2017Date of Patent: October 24, 2023Assignee: STICHTING VUMCInventors: Arjan Willem Griffioen, Elisabeth Johanna Maria Huijbers, Patrycja Nowak-Sliwinska
-
Patent number: 11780893Abstract: The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.Type: GrantFiled: February 24, 2022Date of Patent: October 10, 2023Assignee: Zealand Pharma A/SInventors: Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen
-
Patent number: 11773136Abstract: Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH2.Type: GrantFiled: April 8, 2021Date of Patent: October 3, 2023Assignee: Stealth BioTherapeutics Inc.Inventor: Scott M. Duncan
-
Patent number: 11766480Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.Type: GrantFiled: March 28, 2018Date of Patent: September 26, 2023Assignee: NEW YORK UNIVERSITYInventors: Kent Kirshenbaum, Paul Michael Levine, Michael John Garabedian, Justin M. Holub
-
Patent number: 11746141Abstract: The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparing the modified collagen and uses thereof.Type: GrantFiled: August 9, 2019Date of Patent: September 5, 2023Assignee: INNOCOLL PHARMACEUTICALS LIMITEDInventors: Alexandra Dietrich, Michael Myers
-
Patent number: 11739162Abstract: The current invention pertains compositions and methods to generate compositions providing stability to biomolecules, including providing physiologically stable and functional DNA origami-based drug/gene delivery carriers by surface coating with the oligo-ethylene glycol conjugated peptoids of Formulas (I), (II), and (III).Type: GrantFiled: September 9, 2020Date of Patent: August 29, 2023Assignees: Brookhaven Science Associates LLC, The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California, The Trustees of Columbia University in the City of New YorkInventors: Shih-Ting Wang, Oleg Gang, Ronald N. Zuckermann, Carolyn R. Bertozzi
-
Patent number: 11680088Abstract: The disclosure concerns snake-derived peptides and the useful application of such peptides to inhibit bacterial, fungal, viral and parasitic infections. The disclosed peptides are also useful for the treatment of an inflammatory condition or cancers.Type: GrantFiled: September 17, 2019Date of Patent: June 20, 2023Assignees: Universiteit Leiden, Academisch Ziekenhuis Leiden h.o.d.n. LUMCInventors: Harald Martijn Ijsbrand Kerkkamp, Michael Keith Richardson, Gilles Philippus van Wezel, Jan Wouter Drijfhout, Robert Alexander Cordfunke, Michella Manon Voet, Petrus Hendricus Nibbering
-
Patent number: 11680091Abstract: The current application describes various compositions and methods for the production of FN3-based binding proteins with improved stability properties. Aspects of the disclosure relate to polypeptides comprising a variant fibronectin type III (FN3) domain from Sulfolobus tokodaii or Pyrococcus horikoshii comprising one or more amino acid substitutions or insertions in a loop region of FN3, in a non-loop region of FN3, or in both.Type: GrantFiled: February 21, 2019Date of Patent: June 20, 2023Assignee: The University of ChicagoInventors: Shohei Koide, Shun-Ichi Tanaka, Akiko Koide